The long term objective of this research application is to examine the epigenetic mechanisms that participate in human cancer, and to determine how distinct genetic mutations cooperate and/or influence epigenetic control. Cytosine methylation of CpG dinucleotides in gene regulatory regions is an important epigenetic mechanism involved in gene silencing, whereas, mutations in critical transcription factors, such as p53, is an example of a genetic mechanism involved in silencing target genes. We provide evidence that aberrant cytosine methylation and p53 mutation can cooperate to silence genes with tumor suppressor function. We hypothesize pharmacologic strategies that target epigenetic and genetic lesions can synergize to transcriptionally reprogram cells to a near normal state that will result in efficient tumor cell kill or reversal of malignant properties.
Three Specific Aims are proposed to address the hypothesis and investigate in greater detail the cooperation between genetic and epigenetic mechanisms in the control of gene expression. Studies will focus on human breast cancer; however, the general rules identified will likely extend to other human cancers. 1) Determine if p53 plays a role in the maintenance of the unmethylated state of target gene promoters. 2) Define further the mechanism by which reversal of genetic and epigenetic lesions synergize to reactivate silenced genes. 3) Identify new genes that are controlled by 5-methylcytosine in breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA065662-11
Application #
7126006
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Okano, Paul
Project Start
1996-05-01
Project End
2010-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
11
Fiscal Year
2006
Total Cost
$244,769
Indirect Cost
Name
University of Arizona
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Vrba, Lukas; Garbe, James C; Stampfer, Martha R et al. (2015) A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics 10:1074-83
Yassine, Hussein; Borges, Chad R; Schaab, Matthew R et al. (2013) Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl 7:528-40
Novak, Petr; Stampfer, Martha R; Munoz-Rodriguez, Jose L et al. (2012) Cell-type specific DNA methylation patterns define human breast cellular identity. PLoS One 7:e52299
Teoh-Fitzgerald, Melissa L T; Fitzgerald, Matthew P; Jensen, Taylor J et al. (2012) Genetic and epigenetic inactivation of extracellular superoxide dismutase promotes an invasive phenotype in human lung cancer by disrupting ECM homeostasis. Mol Cancer Res 10:40-51
Vrba, Lukas; Garbe, James C; Stampfer, Martha R et al. (2011) Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 21:2026-37
Vrba, Lukas; Jensen, Taylor J; Garbe, James C et al. (2010) Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 5:e8697
Novak, Petr; Jensen, Taylor J; Garbe, James C et al. (2009) Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 69:5251-8
Novak, Petr; Jensen, Taylor; Oshiro, Marc M et al. (2008) Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res 68:8616-25
Novak, Petr; Jensen, Taylor; Oshiro, Marc M et al. (2006) Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 66:10664-70